Proactive Investors - Run By Investors For Investors

Beaufort Securities Breakfast Alert : Galileo Resources and Hutchison China Meditech

Beaufort Securities Breakfast Alert : Galileo Resources and Hutchison China Meditech

The FTSE-100 finished yesterday's session 0.13% lower at 7,168.01, whilst the FTSE AIM All-Share index was down 0.04% at 1,016.84. In continental Europe, the CAC-40 finished 0.60% lower at 5,109.24 whilst the DAX was down 0.70% at 12,196.50.
Wall Street
Last night in New York, the Dow gained 39.18 points, or 0.16%, to end the day at 24,640.45. The S&P 500 added 6.94 points, or 0.26%, to close at 2,662.94 and NASDAQ finished 31.55 points higher at 7,013.51.
In Asia this morning, the Nikkei 225 was down 63.12 points at 21,181.56 heading into the close. The Hang Seng was 357.44 points higher at 30,196.97 and the Shanghai Composite was up 8.06 points at 3,193.02.
At around 6:15am, WTI crude was unchanged at $59.19 per barrel and Brent was up 0.16% at $62.82 per barrel.

Japan GDP slows to 0.5% in final quarter of 2017
Japan's economic growth slowed in the last three months of 2017 and missed expectations, preliminary official figures show. The world's third-largest economy expanded at an annualised rate of 0.5% in the quarter, against analyst forecasts of 0.9%. But it is still the country's eighth consecutive quarter of growth - the longest streak since the late 1980s. The GDP figures compare with annualised growth of 2.2% in the previous quarter. Annualised growth rates represent a value of growth if the quarter-on-previous quarter rate of change were maintained for a full year.
Source: BBC News

Company news

Galileo Resources (LON:GLR, 1.60p) – Speculative Buy
Galileo Resources announced yesterday encouraging initial results from its 51% owned Star Zinc project in Zambia. The Company has completed 750m of an estimated 1,750m drill campaign comprising 19 vertical and inclined holes up to a depth of 70m. Whilst assay results are still pending, 68% of the drill holes to date intersected high-grade zinc mineralisation based on hand-held XRF spectrometry. Highest point values obtained by the XRF was 52% Zn (willemite) and the averages of three point readings over mineralised intervals returned between 15% Zn and 28% Zn. Based on these initial results the mineralised zone has a strike length, to date, of 100m and remains open along strike and at depth. Galileo holds a 51% interest in the project with the right to increase to 85%. The Star Zinc project is a historical small-scale open pit that operated intermittently between 1950s and 1990s and has a non-compliant (historical) resource estimate of 275kt grading 20.2% Zn based on a cut-off grade of 14% Zn. The Star Zinc project has a four-year exploration permit and is currently under application for a further four-year period.

Our view: We are encouraged with the initial XRF data of up to 52% Zn and look forward to assay results in the coming weeks. In the meantime, we note that historical resource is based entirely vertical drill holes while Galileo has now drilled inclined holes which suggest that mineralisation may be associated with a series of E-W structures. We look forward to further exploration work as the Company continues delineate a 4.4km long geochemical anomaly defined by >100ppm Zn from XRF data. We also note that the Zn mineralisation is hosted in mainly limestone and this style of mineralisation may also contain anomalous silver contents. We maintain a speculative buy on the stock.

Beaufort Securities acts as corporate broker to Galileo Resources PLC

Hutchison China MediTech (LON:HCM, 4,490.00p) – Buy
Hutchison China MediTech (‘Chi-Med’), yesterday announced that it has completed the enrolment of 527 patients in China for pivotal Phase III trial of fruquintinib (jointly developed with Eli Lilly) in advanced non-small cell lung cancer (‘NSCLC’). Top-line data is expected to be reported in H2 2018.

Our view: Good progress for Chi-Med. This trials for NSCLC comes after the Phase II trials showed positive data with no unexpected safety issues. It is also worth noting that the same molecule (fruquintinib) has demonstrated positive results last year for the treatment of third-line colorectal cancer, which is now pending NDA approval in China. Chi-Med is scheduled to release its full year results on 12 March 2018 with a financial guidance includes revenue of US$225-240m, administrative expenses, interest & tax of US$18-19m and net loss of US$13-28m. We reiterate out Buy recommendation on the shares.

Important Risk Warnings and Disclaimers 

This report is published by Beaufort Securities Ltd ("Beaufort Securities"). Beaufort Securities Ltd is Authorised and Regulated by the Financial Conduct Authority and is a Member of the London Stock Exchange. 


This document is not an offer to buy or sell any security or currency. This document does not provide you with individually tailored investment advice. It has been prepared without regard to the your financial circumstances and objectives The appropriateness of a particular investment or currency will depend on your individual circumstances and objectives. The investments and shares referred to in this document may not be suitable for you. 

This research is non-independent and is classified as a Marketing Communication under FCA rules. As such it has not been prepared in accordance with legal requirements designed to promote independence of investment research and it is not subject to the prohibition on dealing ahead of the dissemination of investment research in COBS 12.2.5. However Beaufort Securities has adopted internal procedures which prohibit analysts from dealing ahead of non-independent research, except for legitimate market making and fulfilling clients' unsolicited orders. 

By receiving this document, you will not be deemed a client or provided with the protections afforded to clients of Beaufort Securities. When distributing this document, Beaufort Securities is not acting for you and will not be responsible for providing advice to you in relation to this document. Accordingly, Beaufort Securities will not be responsible to you for providing the protections afforded to its clients. 

Beaufort Securities may effect transactions in shares mentioned herein and may take proprietary trading positions in those shares, and may receive remuneration for the publication of its research and for other services. Beaufort Securities may be a shareholder in any of the companies mentioned in this report. Accordingly, this document may not be considered as objective or impartial. Additionally, information may be available to Beaufort Securities or the Group, which is not reflected in this material. The remuneration of the author of this report is not tied to the recommendations on any shares mentioned nor to the any transactions undertaken by Beaufort Securities or any affiliate company. Further information on Beaufort Securities' policy regarding potential conflicts of interest in the context of investment research and Beaufort Securities' policy on disclosure and conflicts in general are available on request. Please refer to 

Past performance is not a guarantee of future performance. Investments may go down in value as well as up and you may not get back the full amount invested. The listing requirements for securities listed on AIM or the ICAP Securities & Derivatives Exchange are less demanding and trading in them may be less liquid than main markets. This may make it more difficult to buy and sell these securities. 


This document includes certain statements, estimates, and projections with respect to the anticipated future performance of securities listed on stock exchanges and as to the market for these shares. Such statements, estimates, and projections are based on information that we consider reliable and may reflect various assumptions made concerning anticipated economic developments, which have not been independently verified and may or may not prove correct. No representation or warranty is made as to the accuracy of such statements, estimates, and projections or as to its fitness for the purpose intended and it should not be relied upon as such. Opinions expressed are our current opinions as of the date appearing on this material only and may change without notice. Other third parties may have issued other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect the different assumptions, views, and analytical methods of the analysts who prepared them. This report has not been disclosed to any of the companies mentioned herein prior to its publication. 

This document is based on information Beaufort Securities has received from publicly available reports and industry sources. Beaufort Securities may not have verified all of this information with third parties. Neither Beaufort Securities nor its advisors, directors or employees can guarantee the accuracy, reasonableness or completeness of the information received from any sources consulted for this publication, and neither Beaufort Securities nor its advisors, directors or employees accepts any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection with this document (except in respect of wilful default and to the extent that any such liability cannot be excluded by the applicable law). You should not rely on this document and should not use it substitution for the exercise of the independent judgment of yourself or your adviser. 

The information contained in this document is confidential and is solely for use of those persons to whom it is addressed and may not be reproduced, further distributed to any other person or published, in whole or in part, for any purpose. Other persons who receive this document should not rely on it. Beaufort Securities, its directors, officers and employees may have positions in the securities mentioned herein.


© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use